Evidence map›Paper›PMID 39943808›Full record

ArticleACS nano2025

SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation.

Chengyi Li, Fang Ke, Shuai Mao, Zera Montemayor, Mohamed Dit Mady Traore, Alejandra Duran Balsa, Mahamadou Djibo, Neha Karekar, Hongxiang Hu, Hanning Wen and 2 more

Abstract read
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Oncolytic virus M1 reinvigorates CD8Cellular & molecular immunology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chengyi LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-2378-6408
Fang KeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Shuai MaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Zera MontemayorDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mohamed Dit Mady TraoreDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Alejandra Duran BalsaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mahamadou DjiboDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Neha KarekarDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Hongxiang HuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Hanning WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Wei GaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-5233-3734
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-6406-2126

Funding

Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer EfficacyR01CA285790 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Wei Gao, DUXIN SUN · 2024 to 2026
$1.6M
NCI NIH HHS R01 CA285790
6 · The paper itself

Abstract

Current neoantigen cancer vaccines activate T cell immunity through dendritic cell/macrophage-mediated antigen presentation. It is unclear whether incorporating B cell-mediated antigen presentation into current neoantigen vaccines could enhance CD4/CD8 T cell immunity to improve their anticancer efficacy. We developed SARS-CoV-2 B cell epitope-guided neoantigen peptide/mRNA cancer nanovaccines (B

Indexed as

Antigen PresentationAntigens, NeoplasmB-LymphocytesCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19Epitopes, B-LymphocyteSARS-CoV-2AnimalsCell Line, TumorFemaleHumansMiceMice, Inbred C57BLNanovaccinesAntigens, NeoplasmCancer VaccinesEpitopes, B-LymphocyteNanovaccinesB cell-dependent tumor-specific CD8 T cell immunityB cell-mediated antigen presentationB cell receptor cross-linkingneoantigen peptide/mRNA cancer nanovaccineSARS-CoV-2 B cell epitopetumor immunotherapytumor-specific follicular/nonfollicular CD4 T cells

Identifiers

PMID39943808
PMCPMC12664698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.